Linking TGF-β-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160ROCK signaling

Cell Cycle

Volumn 3, Issue 4, 2004, Pages 408-410

  Brown, Kimberly ^a   Bhowmick, Neil A ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Actin; Cdc25A; G1 S cell cycle arrest; RhoA; TGF

Indexed keywords

PROTEIN CDC25A; PROTEIN P160ROCK; PROTEIN TYROSINE PHOSPHATASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CDC25A PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; RHO KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE;

CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CYTOSKELETON; EMBRYO; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; EPITHELIUM CELL; GENOME; GENOTOXICITY; GROWTH INHIBITION; MESENCHYME CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN FUNCTION; REVIEW; ANIMAL; ARTICLE; CELL CYCLE; CELL DIVISION; CELL STRAIN 3T3; DISEASE COURSE; HUMAN; METABOLISM; NEOPLASM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CDC25 PHOSPHATASE; CELL CYCLE; CELL DIVISION; CYTOSKELETON; DISEASE PROGRESSION; G1 PHASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASMS; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RHOA GTP-BINDING PROTEIN; S PHASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 3442898055     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29:117-29.
2. Akhurst RJ, Derynck R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 2001; 11:S44-51.
3. Caulin C, Scholl FG, Frontelo P, Gamallo C, Quintanilla M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-β1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ 1995; 6:1027-35.
4. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, et al. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 1998; 9:393-404.
5. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol 1992; 118:715-26.
6. Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA. Consequences of altered TGF-β expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene 2002; 21:108-18.
7. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, et al. Role of transforming growth factor-β1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17:607-14.
8. Steiner MS, Barrack ER. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992; 6:15-25.
9. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993; 53:4391-8.
10. Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 1992; 28:641-4.
11. Walker RA, Dearing SJ, Gallacher B. Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 1994; 69:1160-5.
12. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990; 87:7678-82.
13. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-54.
14. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23:912-23.
15. Korchynskyi O, Landstrom M, Stoika R, Funa K, Heldin CH, ten Dijke P, Souchelnytskyi S. Expression of Smad proteins inhuman colorectal cancer. Int J Cancer 1999; 82:197-202.
16. Pouliot F, Labrie C. Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens. Int J Cancer 1999; 81:98-103.
17. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12:27-36.
18. ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 2003; 100:15548-53.
19. Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, et al. TGF-β1 inhibition of c-myc transcription and growth in kerarinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 1990; 61:777-85.
20. Pietenpol JA, Holt JT, Stein RW, Moses HL. Transforming growth factor β1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci USA 1990; 87:3758-62.
21. Munger K, Pietenpol JA, Pittelkow MR, Holt JT, Moses HL. Transforming growth factor β1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ 1992; 3:291-8.
22. Zentella A, Massague J. Transforming growth factor β induces myoblast differentiation in the presence of mitogens. Proc Natl Acad Sci USA 1992; 89:5176-80.
23. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995; 55:1452-7.
24. Mulder KM, Levine AE, Hernandez X, McKnight MK, Brattain DE, Brattain MG. Modulation of c-myc by transforming growth factor-β in human colon carcinoma cells. Biochem Biophys Res Commun 1988; 150:711-6.
25. Mulder KM, Brattain MG. Alterations in c-myc expression in relation to maturational status of human colon carcinoma cells. Int J Cancer 1988; 42:64-70.
26. Chen CR, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell 2002; 110:19-32.
27. WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci USA 1998; 95:6733-8.
28. Ink4B transcription in response to TGF-β. EMBO J 2000; 19:5178-93.
29. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995; 9:1831-45.
30. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997; 11:492-503.
31. Datto MB, Yu Y, Wang XF. Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 1995; 270:28623-8.
32. Iavarone A, Massague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 1997; 387:417-22.
33. 1 in human prostate epithelium. J Endocrinol 1999; 160:257-66.
34. INK4b. Nat Cell Biol 2001; 3:400-8.
35. Ink4B. Mol Cell 2002; 9:133-43.
36. INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001; 3:392-9.
37. INK4B induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 1999; 274:35053-8.
38. WAF1/CIP1 promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA, 2001; 98:4510-5.
39. Waf1/Cip1 regulation by transforming growth factor-β. J Biol Chem 2000; 275:29244-56.
40. Nagahara H, Ezhevsky SA, Vocero-Akbani AM, Kaldis P, Solomon MJ, Dowdy SF. Transforming growth factor β targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc Natl Acad Sci USA 1999; 96:14961-6.
41. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81:682-7.
42. Moscow JA, He R, Gnarra JR, Knutsen T, Weng Y, Zhao WP, et al. Examination of human tumors for rhoA mutations. Oncogene 1994; 9:189-94.
43. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002; 87:635-44.
44. Zheng SL, Mychaleckyj JC, Hawkins GA, Isaacs SD, Wiley KE, Turner A, et al. Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. Mutat Res 2003; 528:45-53.
45. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003; 278:10824-30.
46. Nagaraja GM, Kandpal RP. Chromosome 13q12 encoded Rho GTPase activaring protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochem Biophys Res Commun 2004; 313:654-65.
47. Arthur WT, Noren NK, Burridge K. Regulation of Rho family GTPases by cell-cell and cell-matrix adhesion. Biol Res 2002; 35:239-46.
48. 1 phase is controlled by Rho. Nat Cell Biol 2001; 3:950-7.
49. ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 2003; 100:15548-53.
50. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12:27-36.